Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Interstitial Lung Disease Reported in 5 Patients Taking Alimta: PMS
October 8, 2007
-
ARCHIVE Korosho Ready to Reward Innovation: Mr Takeda
October 8, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
October 8, 2007
-
ARCHIVE Paltac and Kobashou to Merge in April 2008
October 8, 2007
-
ARCHIVE New Vision for Medical Device Industry to Call For Fusion of Drugs and Devices
October 8, 2007
-
ARCHIVE Banyu Mounts Sales Drive for Once-Weekly Fosamac
October 8, 2007
-
ARCHIVE Combined Sales Up 13.8% for JGPMA Member Companies
October 1, 2007
-
ARCHIVE Survey:Survey Shows 90% of IBS Patients Not Aware They Have a Disease
October 1, 2007
-
ARCHIVE Domestic Drug Makers Enthusiastic about Partnering with Japanese Bioventures
October 1, 2007
-
ARCHIVE Primary Doctor System Proposed by Korosho Interferes with Patients' Free Access to Medical Services: JMA
October 1, 2007
-
ARCHIVE Biopharmaceuticals to Account for 45% of Sales in 2010: Wyeth
October 1, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
October 1, 2007
-
ARCHIVE Pharma Summit at Bio Japan 2007
October 1, 2007
-
ARCHIVE 41% of Adults Have Undergone Upper GI Endoscopy: Olympus Awareness Survey
October 1, 2007
-
ARCHIVE MTPC to Develop Flexible Computer Systems to Quickly Respond to Market Changes
October 1, 2007
-
ARCHIVE DSM to Expand Lineup of Materials for Devices in the Field of Orthopedic Surgery
October 1, 2007
-
ARCHIVE ASKA Licenses New Oral Formulation Technology from LINTEC
October 1, 2007
-
ARCHIVE Tokyo Boeki Machinery to Launch BIOLIS mini
October 1, 2007
-
ARCHIVE Oncodesign Hosts Japanese Pharma Industry Group
October 1, 2007
-
ARCHIVE Olympus to Launch Capsule Endoscope System in US
October 1, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…